Blood microRNA markers for chemotherapy-related peripheral nerve damage in lung and colorectal cancer
Official title: Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients
Run by University Hospital, Clermont-Ferrand · NCT07427537 · Data updated 2026-11-12
This study will test whether levels of tiny blood molecules called microRNAs can predict how often and how badly patients with lung or colorectal cancer get nerve damage from certain chemotherapies.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | University Hospital, Clermont-Ferrand Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Clermont-Ferrand) |
| Status | Recruiting |
| Started | January 29, 2026 |
| Main results expected | July 31, 2028 |
| Study ends | July 31, 2028 |
| Registry record updated | February 23, 2026 |
| Trial ID | NCT07427537 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults treated for colorectal cancer scheduled for at least six cycles of oxaliplatin or adults treated for lung cancer scheduled for at least four cycles of paclitaxel, without pre-existing neuropathy, major neurodegenerative disease, high baseline pain, or pregnancy.
✕Probably not a fit
Patients with pre-existing neuropathy, significant baseline pain, neurodegenerative disease, recent stroke, or those not receiving the specified chemotherapy regimens are unlikely to benefit from the study findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Patients starting oxaliplatin-based adjuvant chemotherapy for colorectal cancer or paclitaxel-based chemotherapy for lung cancer will be enrolled and followed through their treatment cycles. Blood samples will be taken to measure circulating microRNAs and neurofilament light chain, while clinicians record CIPN grades, QLQ-CIPN20 scores, and neuropathic pain ratings at baseline and during treatment. Investigators will compare molecular marker levels with the timing and severity of chemotherapy-induced peripheral neuropathy to look for predictive patterns. Key exclusions include pre-existing neuropathy, neurodegenerative disease, recent stroke, high baseline pain, pregnancy, or legal protection status to reduce confounding and protect vulnerable participants.
Why it matters
Potential benefit: If successful, this could help identify patients at high risk of chemo-induced nerve damage earlier so clinicians can adjust treatment or offer protective strategies to reduce long-term neuropathy.
How similar studies have gone: Small prior studies have reported promising links between circulating microRNAs (and other blood markers) and chemotherapy neuropathy, but these findings remain preliminary and are not yet validated for clinical use.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles, or * Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles. Exclusion Criteria: * Neurodegenerative disease (e.g., Parkinson's, Alzheimer's, etc.), * History of stroke, * Pre-existing neuropathy (QLQ-CIPN20 sensory score ≥ 15/100), * Pain (NRS ≥ 4/10), * Pregnant or breastfeeding women, * Patients under guardianship, curatorship, deprived of liberty, or under legal protection
Where it's running
-
CHU Clermont-Ferrand
Clermont-Ferrand, France Recruiting
Study contacts
- Principal investigator: David BALAYSSAC — University Hospital, Clermont-Ferrand
- Study coordinator: Lise Laclautre
- Email: promo_interne_drci@chu-clermontferrand.fr
- Phone: 334.73.754.963
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Home-use Erchonia EVRL laser for temporary relief of idiopathic peripheral neuropathy foot pain
This study will test whether a home-use Erchonia EVRL laser can provide temporary relief of foot pain for adults with idiopathic peripheral neuropathy.
-
Feasibility of paired non-invasive blood flow and tissue oxygen monitoring to detect limb ischemia during lithotomy-position surgeries
This study tests whether using combined non-invasive blood flow monitoring and tissue oxygen sensors during long lithotomy surgeries can help detect early limb ischemia in adults.
-
Using neuromodulation to treat pain from chemotherapy-induced peripheral neuropathy
This study is testing a new way to relieve pain from nerve damage caused by chemotherapy in patients with lower extremity CIPN.
-
Electrical stimulation to improve recovery after cubital tunnel surgery
This study is testing a new electrical stimulation treatment to see if it helps people recover better after surgery for cubital tunnel syndrome.
-
Evaluating Ketotifen's protective role against chemotherapy-induced nerve damage
This study is testing if Ketotifen can help prevent nerve damage caused by chemotherapy in people with stage III colorectal cancer.
-
Peripheral nerve block for painful diabetic neuropathy
This study is testing if a nerve block can help adults with painful diabetic neuropathy feel less pain without stopping their regular medications.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.